WATERTOWN, Mass.--(BUSINESS WIRE)--Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) today announced the dosing of the first patient in its Phase 3 clinical trial of its lead drug candidate eravacycline for the treatment of complicated intra-abdominal infections (cIAI). The cIAI study is the first of two planned Phase 3 clinical trials of eravacycline: one for the treatment of cIAI and one for the treatment of complicated urinary tract infections (cUTI). This first Phase 3 global study of eravacycline is designed to assess the efficacy and safety of eravacycline compared with ertapenem in cIAI.
Help employers find you! Check out all the jobs and post your resume.
